PI
MRSN

Putnam Investments’s Mersana Therapeutics MRSN Stock Holding History

Putnam Investments’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-28,832
Closed -$11.7M – 822
2021
Q1 		$11.7M Buy
28,832
+6,516
+29% +$3.16M 0.02% 349
2020
Q4 		$14.8M Buy
+22,316
New +$12.4M 0.03% 290

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Putnam Investments's MRSN Position: Q2 2021 in Review

Putnam Investments sold out of Mersana Therapeutics (MRSN) in Q2 2021, closing a stake of 28,832 shares — an estimated $11.7M sold.

Putnam Investments first reported a position in MRSN in Q4 2020 and held it in 2 quarters. The position peaked at $14.8M in Q4 2020. 131 funds tracked by Wall St. Rank hold MRSN as of Q2 2021.

  • Putnam Investments reported no remaining Mersana Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Putnam Investments sold 28,832 Mersana Therapeutics shares in Q2 2021, an estimated $11.7M.
  • Putnam Investments first reported a position in Mersana Therapeutics in Q4 2020 and held it in 2 quarters.
  • Putnam Investments's Mersana Therapeutics position peaked at $14.8M in Q4 2020.
  • 131 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2021.

Based on Putnam Investments's 13F filing for Q2 2021, filed 16 Aug 2021.